Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants.

Wong, Carlos K H; Lau, Kristy T K; Leung, Gabriel M

Wong, Carlos K H; Lau, Kristy T K; Leung, Gabriel M.

Wong CKH; Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China. Electronic address: carlosho@hku.h
Lau KTK; Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Leung GM; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China.

Lancet Infect Dis ; 23(6): 639-640, 2023 06.

Article in English | MEDLINE | ID: covidwho-2237044

Subject(s)

COVID-19; SARS-CoV-2; Humans; SARS-CoV-2/genetics; Ritonavir/therapeutic use; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Variants Limits: Humans Language: English Journal: Lancet Infect Dis Journal subject: Communicable Diseases Year: 2023 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google